TAK Healthcare

Takeda Pharmaceutical Company Limited

$20.75-0.57%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Japan
Market cap: 66.3B USD
Enterprise value: 91.3B USD
Full-time employees: 47,029

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.09 vs a peer median of 2.59) and more debt relative to equity (0.66× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.09 vs peers 2.59) and more debt vs equity (0.66× vs peers 0.22×)
About average: valuation

Ranks #980 of 1,157 healthcare companies (bottom 16%)

See how it ranks against its peers

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.
Takeda Pharmaceutical made a loss per share in its latest year after a profit the year before.
Operating margin at a 6-year low. 0.1% in FY Mar 2026, the weakest of the last 6 years.
Takeda Pharmaceutical's operating margin fell to 0.1% in FY Mar 2026, its lowest in the 6 years of filings we have.
Valuation signals disagree. Cheaper than 55% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 55% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), Takeda Pharmaceutical looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Takeda Pharmaceutical looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Sales growing faster than profits. Since FY Mar 2023: revenue +12%, operating profit −99%.
Since FY Mar 2023, Takeda Pharmaceutical's revenue changed +12% while operating profit fell 99%: costs rose faster than sales.

StockQuotient Score

30/ 100

Oct 5 31 → Nov 4 30 (-1)

Valuation

Is the price right?

44/100

Moderate

3/3 inputs reported · High confidence

Since last year: No major changeValuation also moves with the share price every day.

Why

Held back by:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-1.4%

SEC filings (IFRS mapped) · 12 months to Mar 2026 · JPY→USD at the current rateNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield4.9%

SEC filings (IFRS mapped) · 12 months to Mar 2026 · JPY→USD at the current rateReported value50% base weight · Z-score 0.21Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield8.1%

SEC filings (IFRS mapped) · 12 months to Mar 2026 · JPY→USD at the current rate · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield69.5%

SEC filings (IFRS mapped) · latest balance sheet · JPY→USD at the current rateReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

20/100

Weak

3/3 inputs reported · High confidence

Since last year: No major change

Why

Weaker than most peers on:

▼ EPS growth
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth3.8%

SEC filings (IFRS mapped) · 3 years to Mar 2026Reported value33% base weight · Z-score -0.24Sector median: 0.0584 · MAD: 0.0840

Revenue growth-1.7%

SEC filings (IFRS mapped) · 12 months to Mar 2026Reported value33% base weight · Z-score -0.80Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

37/100

Weak

3/3 inputs reported · High confidence

Since last year: ▼ Weaker

Turned to a loss over the last 12 months
Operating margin fell 7.3 points to 0.1%

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin0.1%

SEC filings (IFRS mapped) · 12 months to Mar 2026Reported value33% base weight · Z-score -0.57Sector median: 0.0706 · MAD: 0.1217

Return on assets-1.0%

SEC filings (IFRS mapped) · 12 months to Mar 2026Reported value33% base weight · Z-score -0.49Sector median: 0.0166 · MAD: 0.0537

Return on invested capital0.0%

SEC filings (IFRS mapped) · 12 months to Mar 2026Reported value33% base weight · Z-score -0.47Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin65.1%

SEC filings (IFRS mapped) · 12 months to Mar 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-2.1%

SEC filings (IFRS mapped) · 12 months to Mar 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

2/3 inputs reported · Partial data

Since last year: ▼ Weaker

Operating profit now covers interest only 0.0x

Why

Weaker than most peers on:

▼ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio1.09×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -1.08Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.66×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -2.14Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Takeda Pharmaceutical

Is Takeda Pharmaceutical getting weaker?: Its latest SEC filing (Jun 17, 2026) got weaker in some ways: turned to a loss over the last 12 months; operating margin fell 7.3 points to 0.1%. Its overall score is unchanged at 30/100 since Oct 28, 2026.
How is Takeda Pharmaceutical valued vs its peers?: Priced about in line with its peers. Valuation scores 44/100 against 1,393 healthcare peers. Earnings yield -1.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.4% vs peers 1.5% (weaker than 100% of peers).
Is Takeda Pharmaceutical growing?: More slowly than most of its peers. Growth scores 20/100 against 1,393 healthcare peers. Revenue growth -1.7% vs a peer median of 6.1% (weaker than 73% of peers).Revenue growth -1.7% vs peers 6.1% (weaker than 73% of peers).
How profitable is Takeda Pharmaceutical?: Less profitable than most of its peers. Profitability scores 37/100 against 1,393 healthcare peers. Operating margin 0.1% vs a peer median of 7.1% (weaker than 67% of peers).Operating margin 0.1% vs peers 7.1% (weaker than 67% of peers).
How risky is Takeda Pharmaceutical?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.09× vs a peer median of 2.59× (weaker than 87% of peers).Current ratio 1.09× vs peers 2.59× (weaker than 87% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Mar 31, 2026 · filed Jun 17, 2026 · compared with the year ended Mar 31, 2025

Got weaker

Turned to a loss over the last 12 months
Operating margin fell 7.3 points to 0.1%
Operating profit now covers interest only 0.0x

	Previous year	Latest year	Change
Revenue (12 months)	4.58T JPY	4.51T JPY	−1.7%
Net income (12 months)	107.9B JPY	−152.4B JPY	turned negative
Operating margin	7.5%	0.1%	−7.3 pts
Free cash flow (12 months)	856.4B JPY	865.4B JPY	+1.1%
Debt	4.52T JPY	4.88T JPY	+8.1%
Cash	385.1B JPY	595.1B JPY	+54.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year · amounts in JPY, as reported

Key ratios	FY Mar 2022	FY Mar 2023	FY Mar 2024	FY Mar 2025	FY Mar 2026	Change
Gross margin	69.0%	69.1%	66.5%	65.5%	65.1%	▼ 0.4 pts
Operating margin	12.9%	12.2%	5.0%	7.5%	0.1%	▼ 7.3 pts
Net margin	6.4%	7.9%	3.4%	2.4%	-3.4%	▼ 5.7 pts
Return on assets (ROA)	1.7%	2.3%	1.0%	0.8%	-1.0%	▼ 1.7 pts
Return on equity (ROE)	4.0%	5.0%	2.0%	1.6%	-2.1%	▼ 3.6 pts
Free cash flow margin	28.0%	20.8%	12.7%	18.7%	19.2%	▲ 0.5 pts
Current ratio	1.21×	0.97×	1.11×	1.01×	1.09×	▲ 8.5%
Quick ratio	0.81×	0.57×	0.58×	0.52×	0.60×	▲ 15%
Debt to equity	0.76×	0.69×	0.67×	0.65×	0.66×	▲ 0.9%
Interest coverage	3.76×	4.19×	1.79×	2.49×	0.04×	▼ 98%

TAK price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.09 vs a peer median of 2.59) and more debt relative to equity (0.66× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.09 vs peers 2.59) and more debt vs equity (0.66× vs peers 0.22×)

About average: valuation

Ranks #980 of 1,157 healthcare companies (bottom 16%)

See how it ranks against its peers

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.

Takeda Pharmaceutical made a loss per share in its latest year after a profit the year before.

Operating margin at a 6-year low. 0.1% in FY Mar 2026, the weakest of the last 6 years.

Takeda Pharmaceutical's operating margin fell to 0.1% in FY Mar 2026, its lowest in the 6 years of filings we have.

Valuation signals disagree. Cheaper than 55% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 55% of peers on operating cash profit, but only 0% on earnings.

Relative to its operating cash profit (EBITDA), Takeda Pharmaceutical looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Takeda Pharmaceutical looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Sales growing faster than profits. Since FY Mar 2023: revenue +12%, operating profit −99%.

Since FY Mar 2023, Takeda Pharmaceutical's revenue changed +12% while operating profit fell 99%: costs rose faster than sales.

Questions investors ask about Takeda Pharmaceutical

Is Takeda Pharmaceutical getting weaker?

Its latest SEC filing (Jun 17, 2026) got weaker in some ways: turned to a loss over the last 12 months; operating margin fell 7.3 points to 0.1%. Its overall score is unchanged at 30/100 since Oct 28, 2026.

How is Takeda Pharmaceutical valued vs its peers?

Priced about in line with its peers. Valuation scores 44/100 against 1,393 healthcare peers. Earnings yield -1.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.4% vs peers 1.5% (weaker than 100% of peers).

Is Takeda Pharmaceutical growing?

More slowly than most of its peers. Growth scores 20/100 against 1,393 healthcare peers. Revenue growth -1.7% vs a peer median of 6.1% (weaker than 73% of peers).Revenue growth -1.7% vs peers 6.1% (weaker than 73% of peers).

How profitable is Takeda Pharmaceutical?

Less profitable than most of its peers. Profitability scores 37/100 against 1,393 healthcare peers. Operating margin 0.1% vs a peer median of 7.1% (weaker than 67% of peers).Operating margin 0.1% vs peers 7.1% (weaker than 67% of peers).

How risky is Takeda Pharmaceutical?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.09× vs a peer median of 2.59× (weaker than 87% of peers).Current ratio 1.09× vs peers 2.59× (weaker than 87% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Revenue (12 months)

4.58T JPY

4.51T JPY

−1.7%

Net income (12 months)

107.9B JPY

−152.4B JPY

turned negative

Operating margin

7.5%

0.1%

−7.3 pts

Free cash flow (12 months)

856.4B JPY

865.4B JPY

+1.1%

Debt

4.52T JPY

4.88T JPY

+8.1%

Cash

385.1B JPY

595.1B JPY

+54.5%

Key ratios

FY Mar 2022

FY Mar 2023

FY Mar 2024

FY Mar 2025

FY Mar 2026

Change

Gross margin

69.0%

69.1%

66.5%

65.5%

65.1%

▼ 0.4 pts

Operating margin

12.9%

12.2%

5.0%

7.5%

0.1%

▼ 7.3 pts

Net margin

6.4%

7.9%

3.4%

2.4%

-3.4%

▼ 5.7 pts

Return on assets (ROA)

1.7%

2.3%

1.0%

0.8%

-1.0%

▼ 1.7 pts

Return on equity (ROE)

4.0%

5.0%

2.0%

1.6%

-2.1%

▼ 3.6 pts

Free cash flow margin

28.0%

20.8%

12.7%

18.7%

19.2%

▲ 0.5 pts

Current ratio

1.21×

0.97×

1.11×

1.01×

1.09×

▲ 8.5%

Quick ratio

0.81×

0.57×

0.58×

0.52×

0.60×

▲ 15%

Debt to equity

0.76×

0.69×

0.67×

0.65×

0.66×

▲ 0.9%

Interest coverage

3.76×

4.19×

1.79×

2.49×

0.04×

▼ 98%